Slide 1: New approvals for Leqembi and additional strategic partnerships
New approvals for Leqembi® and additional strategic partnerships Second quarter 2026 business and financial update 1
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: Presenters and IR contact
Gunilla Osswald Anders Martin-Löf Johanna Fälting Anna-Kaija Grönblad Chief Executive Officer Chief Financial Officer Chief R&D Officer Chief Commercial Officer IR contact: Oskar Bosson, Chief IR & Communications Officer Next Report: Q3 2026 To subscribe to financial reports/press releases and +46 7
Slide 4: Key highlights
Key highlights Gunilla Osswald Chief Executive Officer 4
Slide 5: World-leading innovators in precision neurology
World-leading innovators in precision neurology Highly selective antibodies targeting aggregated forms BrainTransporter platform Modality BrainTransporter of toxic proteins delivers biotherapeutics to the brain accommodate a variety of drug modalities BT Modalities Antibodies Enzymes Proteins Geneti
Slide 6: Delivering on our 2030 ambitions
Delivering on our 2030 ambitions On the path to becoming Sweden’s next major biopharma company 1 2 3 4 Leqembi Broader pipeline Partnerships Strong financials • Iqlik sc autoinjector • Exidavnemab phase 2a • New partnership with Lilly • SEK 2 B in cash launched also as initiation safety review suppo
Slide 7: Partnerships – a key component behind our success
USD 800 M + potential royalties (USD 770 M milestones remaining) 2026 – USD 802 M + potential royalties (USD 772 M milestones remaining) Partnerships 2025 – – a key component USD 1.35 B + potential royalites behind our success (USD 1.25 B milestones remaining) 2024 – EUR 222 M + 9% royalties (EUR 34
Slide 8: R&D update
R&D update Johanna Fälting Chief R&D Officer 8
Slide 9: Two world-leading platforms with cross-program synergies
Two world-leading platforms with cross-program synergies Regulatory Indication Partner Research Preclinical Phase 1 Phase 2 Phase 3 Market phase Antibodies targeting amyloid-beta Lecanemab (IV)1 Alzheimer’s disease Eisai Lecanemab (s.c.)2 Alzheimer’s disease Eisai Lecanemab (presymptomatic treatment
Slide 10: α-synuclein portfolio moving forward and expanding
α-synuclein portfolio moving forward and expanding Offers opportunities in several synucleinopathies α-syn antibodies targeting aggregated misfolded α-synuclein Exidavnemab (α-synuclein antibody) • Safety data from phase 2a study EXIST in Parkinson’s disease (PD) and Multiple System Atrophy (MSA) ev
Slide 11: Validation of BrainTransporter through recent strategic collaborations
Validation of BrainTransporter through recent strategic collaborations • Strong external platform validation • Expanding pipeline outside neurodegeneration • Highlights active blood-brain barrier transport as a • First oncology program (glioblastoma) critical enabler for future CNS therapies • BioAr
Slide 12: Leqembi update
Leqembi update Anna-Kaija Grönblad Chief Commercial Officer 12
Slide 13: Leqembi: New approvals and continued growth
• Global roll-out of subcutaneous initiation treatment starting H2 2026: ⎻ FDA approval July 13, 2026 – launched in August ⎻ Japan: expected approval in Q3 2026, with reimbursement expected in Q4 2026 ⎻ China (priority review): expected approval in H1 2027 ⎻ Data from AAIC show efficacy and safety f
Slide 14: AAIC 2026: Real-world evidence from LEADER study
AAIC 2026: Real-world evidence from LEADER study underlines clinical efficacy and safety profile Clear clinical benefit Patients stay Safety data in on treatment line with label Among patients treated for more than 18 months, Severe ARIA-E was 82.5% 78.9% 0.2% patients were transitioned to Total ARI
Slide 15: Financial summary
Financial summary Anders Martin-Löf Chief Financial Officer 15
Slide 16: Leqembi underlying growth continues
Leqembi underlying growth continues BioArctic royalty • Global Q2-26 sales were ¥ 29.3 B ($ ~184 M), 12% increase from Q1-26 or 27% increase from Q2-25 200 − Q2 royalty grew by 12% QoQ to SEK 179,4 M 179.4 180 − YoY royalty growth was 10%, would have been 43% excluding onetime 162.5 160.8 stockpilin
Slide 17: Leqembi on track to reach 2026 forecast of ¥143.5 B
Leqembi on track to reach 2026 forecast of ¥ 143.5 B Leqembi Global Sales - Actuals & forecast ¥ 143.5 B 160 ($ ~910 M) 140 14.0 +63% 120 19.0 ¥ 88.0 B 100 ($ ~580 M) Other 33.0 Forecast corresponds to 6.6 China royalty of SEK~880 M ¥B 80 12.4 Japan Q2-2026 to Q1-2027 60 24.4 North America 40 77.5 2
Slide 18: Small operating loss - no revenues from Lilly agreement recorded in Q2
Small operating loss - no revenues from Lilly agreement recorded in Q2 Net Revenues (SEK M) OPEX by function (SEK M) Operating Profit/Loss (SEK M) • Q2 net revenues SEK 248 M (392) • Operating expenses increased to • Operating profit was • No milestones in the quarter vs. SEK 223 M SEK 232 M (193) i
Slide 19: Very solid financial position with SEK 2 B in cash end of Q2
Very solid financial position with SEK 2 B in cash end of Q2 USD 30 M received from Lilly after the end of the period Net Result (SEK M) Cash Flow From Operating Cash Balance (SEK M) Activities (SEK M) Net profit for Q2 was Operating cash flow was Cash, cash equivalents and SEK -11 M (97) SEK 138 M
Slide 20: Upcoming news flow and closing remarks
Upcoming news flow and closing remarks 20
Slide 21: Recent and upcoming news flow
Recent and upcoming news flow Q3 2026 Q4 2026 Q1 2027 Q2 2027 Congresses AAIC CTAD AD/PD US approval & launch Potential Japanese Potential Chinese approval Leqembi SC-AI of Leqembi Iqlik SC-AI reimbursement initiation treatment initiation treatment approval Start of Potential Japanese exidavnemab Ph
Slide 22: Key takeaways
Key takeaways 1 Continued progress for Leqembi: Iqlik launched in the US for initiation treatment 2 Landmark deal with Eli Lilly 3 Project portfolio expanded into new therapeutic area 4 Strong financial position: SEK 2 billion in cash 22
Slide 23: A world where science defeats severe brain diseases
With patients in mind we are committed to our vision: A world where science defeats severe brain diseases 23